Late-Breaking Phase 2 MSS mCRC with high plasma TMB data for vilastobart + atezolizumab at SITC.

40% ORR
https://ir.xiliotx.com/news-releases/news-rel...ase-2-data


"Based on the differentiated profile demonstrated by vilastobart as a combination therapy, Xilio is actively seeking a partner to continue to develop vilastobart in combination with PD-(L)1 and/or PD1-VEGF in MSS CRC and other tumor types."

Can't wait for us to start releasing results...